ReviewESMO gastrointestinal oncology2025
Expanding the potential of antibody-drug conjugates in gastrointestinal malignancies: beyond HER2 targets.
Review in ESMO gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Biological and Targeted Therapies in the Multidisciplinary Management of Gastrointestinal Cancers.Cancers · 2026Review
- Engineering biopolymer nanoparticles for targeted nanomedicine in cancer therapy and food preservation.Frontiers in nutrition · 2026Review
- Global variations in oncology professionals' confidence levels for managing antibody-drug conjugate toxicities: a cross-continental survey.The oncologist · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibody-drug conjugates (ADCs) are an emerging class of targeted cancer therapeutics, combining the specificity of monoclonal antibodies with the potency of cytotoxic agents to deliver localized treatment while minimizing off-target effects. Recent advancements in ADC design focus on optimizing payloads, improving linker stability, and selecting effective target antigens. Additionally, innovative approaches such as small-molecule drug conjugates, immune-stimulating payloads, and bispecific or biparatopic antibodies are being explored to enhance specificity and efficacy. Despite challenges like neutralizing antibodies, toxicity, and variable efficacy, several ADCs have shown promise in patients with solid tumours. Particularly, in gastrointestinal cancers, ADCs targeting antigens such as claudin 18.2, c-MET, and CEACAM5 have demonstrated clinical activity offering potential alternatives to traditional human epidermal growth factor receptor 2 (HER2)-based therapies. Ongoing efforts to refine ADCs and explore novel formats offer significant potential to transform the treatment landscape of gastrointestinal cancers. This review examines the current state of ADC development for gastrointestinal malignancies, focusing on emerging targets and strategies beyond HER2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.